Determining a commercialisation strategy

M.A.R.S Ltd provided a detailed cost consequence model for our new proprietary technology. The model has been enormously helpful in determining our commercialisation strategy as we take our product towards clinical testing. We anticipate that the model will also realise financial benefits for our company through demonstrating and evidencing the market potential of, and reimbursement pathways for, our technology to investors

Professor James Birchall PhD FHEA
Professor of Pharmaceutical Sciences